Can Complete Blood Count Picture Tell Us More About the Activity of Rheumatological Diseases?

Sara I Taha1, Sara F Samaan2, Rehab Ali Ibrahim3, Nouran M Moustafa4,5, Eman M El-Sehshah6 and Mariam K Youssef7

1Department of Clinical Pathology/Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 2Department of Internal Medicine/Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 3Department of Physical Medicine/Rheumatology and Rehabilitation, Faculty of Medicine, Ain-Shams University, Cairo, Egypt. 4Basic Medical Science Department, College of Medicine, Dar Al Uloom University, Riyadh, Saudi Arabia. 5Medical Microbiology and Immunology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 6Department of Medical Microbiology and Immunology, Mansoura Faculty of Medicine, Mansoura, Egypt. 7Department of Clinical Pathology/Hematology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

ABSTRACT

BACKGROUND: In clinical practice, distinguishing disease activity in patients with rheumatological illnesses is challenging.

OBJECTIVES: We aimed to investigate clinical associations of hemogram-derived indices, namely: red cell distribution width (RDW), mean platelet volume (MPV), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and systemic immune-inflammation index (SII) with disease activity in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and ankylosing spondylitis (AS).

METHODS: In 250 patients with rheumatological disease and 100 healthy age-matched controls, we investigated disease activity scores and indicators and evaluated their association with hemogram-derived indices values.

RESULTS: Compared with the control group, RDW, MPV, and PLR significantly increased (P < .001) in the three studied disorders (RA, SLE, and AS), but LMR dramatically decreased. SII was considerably higher in RA and AS patients compared with controls but not in SLE patients. On the other hand, NLR rose dramatically in SLE patients compared with controls (P = .043), but did not change much in RA and AS patients (P > .05). RDW and MPV showed significant changes (P < .001) in the three studied diseases (RA, SLE, and AS) according to disease activity. They significantly increased across worsening activity scores. Only in the SLE group, PLR was significantly increased with disease activity (P < .001), while LMR showed a significant decrease (P = .016).

CONCLUSIONS: Clinicians must pay close attention to complete blood count (CBC) analysis and its various derived ratios to better characterize the activity of rheumatological disorders and anticipate the disease course and prognosis.

KEYWORDS: Ankylosing spondylitis, complete blood count, hemogram-derived ratios, rheumatoid arthritis, systemic lupus erythematosus

Introduction

Inflammation is the primary determinant and the critical pathogenic mechanism in many connective tissue diseases; the inflammatory process, if uncontrolled, can result in significant disabilities with increased mortality.1 Systemic lupus erythematosus (SLE) is an inflammatory disease characterized by the generation of autoantibodies and immune complexes with end-organ damage (especially the kidneys).2 Even with appropriate management, SLE patients may continue to have disease activity up to 10 years after diagnosis.3 Rheumatoid arthritis (RA) is an autoimmune inflammatory disorder affecting several organs, particularly the synovial membranes of joints, which results in joint degeneration, and poor quality of life.4 Ankylosing spondylitis (AS), the archetype of spondyloarthropathies, is a chronic inflammatory condition that mostly affects the sacroiliac joint and spine.5 Although AS is a slowly progressive disorder, spine involvement is progressive, and the inflammation can persist even years after the diagnosis,6 leading to serious mobility problems and restricted social life.7 As a result, using reliable markers to measure inflammation in collagen and connective tissue diseases is critical for monitoring disease activity and predicting patient outcomes. The most commonly used markers in daily practice are erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).

On the other hand, these indicators have a limited ability to distinguish between disease flare and superimposed infections.8

DECLARATION OF CONFLICTING INTERESTS: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

CORRESPONDING AUTHOR: Sara I Taha, Department of Clinical Pathology/Immunology, Faculty of Medicine, Ain Shams University, Abassia, Cairo 11591, Egypt. Email: dr_sara_it@med.asu.edu.eg

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
The complete blood count (CBC) is a simple, inexpensive, and time-effective test used routinely for rheumatology patients to monitor medication side effects and possible disease-related changes. Systemic inflammation is linked to changes in circulating blood cells. Many inflammatory disorders are accompanied by normochromic anemia, thrombocytosis, neutrophilia, lymphopenia, and monocytosis. As a result, inflammatory activity can be assessed using the characteristics of circulating blood cell components. Neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) are widely accepted and useful tools for the evaluation of inflammatory activity in many chronic inflammatory disorders. Moreover, the red cell distribution width (RDW), the mean platelet volume (MPV), and the systemic immune-inflammation index (SII) have emerged as biomarkers of inflammation and disease activity in a variety of diseases.

MPV is a surrogate marker of platelet activation, and has been associated with a number of inflammatory conditions, including functional bowel diseases, obesity, infections, diabetes mellitus (DM), vertebral disk conditions, and cardiac diseases. On the other hand, RDW is a marker of anisocytosis and is associated with certain inflammatory conditions, such as thyroiditis, autoimmune hepatitis, malignant conditions, and type 2 DM.

As a hemogram-derived marker, NLR has been reported to be associated with inflammatory bowel disease, irritable bowel syndrome, Hashimoto’s disease, and type 2 DM. Similarly, PLR has been introduced as an inflammatory marker in thyroid conditions, DM, and liver fibrosis. Finally, LMR is suggested to be related with diabetic nephropathy, critical limb ischemia, and cerebral venous sinus thrombosis.

Our study was intended to detect whether the hemogram-derived ratios and indices (NLR, LMR, PLR, RDW, MPV, and SII) in RA, SLE, and AS patients were affected and whether they were related to the activity of the disease.

Methodology

Study subjects and settings

The PASS 11 Program was used for sample size calculation, setting power at 80% and α-error at 0.05. It was estimated that a sample size of 75 patients will be adequate to detect an expected area under receiver operating characteristic (ROC) curve of 0.70 for measured ratios to differentiate between active and inactive cases (assuming 30% of patients have active disease according to Kiscik et al.).

This case-control study included; 250 adult patients (age ≥ 18 years old) with rheumatological diseases (100 patients with SLE, 100 with RA, and 50 with AS), who visited the outpatient clinic or were admitted to the inpatient unit of the Rheumatology Department of Ain-Shams University, Cairo, Egypt, during the period from April 1 to June 30, 2021 (within 6 months from their first diagnosis). The study also included 100 healthy adult age-matched subjects as control. All included participants were subjected to detailed history taking stressing on age, gender, and presenting symptoms, and a thorough clinical examination. Patients with SLE were diagnosed using the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria, RA patients with the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria, and AS patients with the 2009 Assessment of Spondyloarthritis International Society (ASAS) criteria. Those who were pregnant or up to 6 months postpartum or had blood, liver, kidney, heart, or thyroid disorders, concomitant autoimmune diseases, infections, or malignancies were all excluded from the study.

Evaluation of disease activity

The disease activity of SLE patients was assessed using the systemic lupus erythematosus disease activity index (SLEDAI) scoring system, which classified patients with a score of < 6 as clinically inactive, 6 to 12 as having mild to moderate disease activity, and > 12 as having severe disease activity. The disease activity of RA patients was assessed using the disease activity score-28 (DAS-28), which classified patients with a score of < 2.6 as remitted, patients with a score of 2.6 to 3.1 as low active, patients with a score of 3.2 to 5.0 as moderately active, and patients with a score of > 5.1 as highly active.

Regarding AS patients, we rated pain on a 10-point scale (1 being the least severe and 10 being the most severe) and by the ankylosing spondylitis disease activity score (ASDAS), we used three cut-offs (1.3, 2.1, and 3.5) to distinguish AS inactive and moderate, high and very high disease activity.

Laboratory investigations

Two ml EDTA anticoagulated venous blood samples from each participant were aseptically withdrawn for CBC with differential count analysis, using the Sysmex XT-1800i autoanalyzer (Sysmex, Japan). We calculated ratios between neutrophil and lymphocyte counts (NLR), lymphocyte and monocyte counts (LMR), and platelet and lymphocyte counts (PLR). We also calculated the SII by multiplying the neutrophil count by platelet count and dividing by the lymphocyte count. RDW, which reflects the variability in red cell sizes, was calculated by the instrument by dividing the standard deviation of mean cell size by the mean corpuscular volume (MCV) of the red cells and multiplying by 100. Also, the MPV was calculated by the instrument by dividing the total mass of the platelets (platelet-crit) by the total number of platelets.

In SLE patients, an additional 3 ml of blood was collected into a serum separation tube. Serum samples were used to determine anti-double-stranded DNA antibody titer.
(anti-dsDNA) by indirect immunofluorescence technique (slides were supplied by Inova Diagnostics, Inc., San Diego, USA, REF: 508200.10) and complement levels by a COBAS Auto-analyzer (Roche Diagnostics, Mannheim, Germany).

In RA patients, an additional 3 ml of blood was collected into a serum separation tube. Serum samples were used for rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) determination by a COBAS Autoanalyzer (Roche Diagnostics, Mannheim, Germany).

An additional 2 ml of blood was collected in AS patients into an EDTA tube used for HLA-B27 typing by the serological method using Terasaki microtiter plates (Inno-Train Diagnostik GmbH, Kronberg, Germany) and Leica DMI3000B Inverted Fluorescence Phase-contrast Microscope (Wetzlar, Germany).

Statistical analysis

For data analysis, IBM SPSS statistics (V. 26.0, IBM Corp., USA, 2019) was used. After describing the data, we used the Wilcoxon rank sum test, Kruskal-Wallis test, and chi-square test to make comparisons. The correlation between parameters was detected using the ranked Spearman correlation test. ROC curve was built and the area under the curve (AUC) was determined to detect the most discriminating markers of disease activity. To discover the most sensitive predictors for disease activity, we used a logistic multi-regression analysis. Results were considered significant at $P < .05$.

Results

This case-control study comprised 100 healthy control and 250 adult rheumatological patients (100 SLE, 100 RA, and 50 AS). Patients and controls were age-matched with no significant differences. More female patients were in RA (81.0%) and SLE (84.0%) groups, while 66.0% were males in the AS group. RDW, MPV, and PLR significantly increased in the three studied groups (RA, SLE, and AS) compared with the control group, while LMR significantly decreased. SII significantly increased in RA and AS patients than controls, while SLE patients showed no significant change. On the other hand, NLR significantly increased in SLE patients than controls but showed no significant change in RA and AS patients. Table 1 demonstrates characteristics and CBC parameters of the included control subjects and RA, SLE, and AS patients.

Disease-specific markers and activity scoring are shown in Table 2. The median (interquartile range [IQR]) DAS 28 score of the included RA patient was 4.4 (2.8–5.9) with a range of 2–8.3, the median (IQR) SLEDAI score of the included SLE patients was 9 (6–13), and ranged from 4 to 20, and the median (IQR) ASDAS score of the included AS patients was 1.9 (1.17–2.82) and ranged from 1 to 3.8.

RDW and MPV showed significant changes in the three studied diseases (RA, SLE, and AS) according to disease activity. They significantly increased across worsening activity scores. Only in the SLE group, PLR was significantly increased with worsening SLEDAI, while LMR showed a significant decrease (Table 3).

Furthermore, RDW and MPV showed significant positive correlations with CRP, ESR, DASs, namely, DAS-28, SLEDAI, and ASDAS in RA, SLE, and AS, respectively. RDW and MPV were also significantly positively correlated with RF and anti-CCP levels in the RA group and anti-ds-DNA titer in the SLE group. PLR in the SLE group, and NLR and SII in the AS group were also significantly positively correlated with activity markers (CRP and ESR) and scores (SLEDAI and ASDAS, respectively). On the contrary, LMR in the AS group significantly negatively correlated with CRP and ESR only but not with the ASDAS score (Table 4).

According to multi-regression analyses, RDW and NLR were the best predictors of RA activity with a regression coefficient of 0.040 and -0.027, and a $P$ of .002 and .049, respectively ($F$ ratio: 7.144; $P = .001$). On the other hand, RDW and MPV were the best predictors of SLE activity with a regression coefficient of 0.035 and 0.058 and a $P$ of .035 and .051, respectively ($F$ ratio: 9.816; $P < .001$). Similarly, RDW and MPV were the best predictors of AS activity; regression coefficients were 0.084 and 0.058; $P$ of <.001 and .003, respectively ($F$ ratio: 32.079; $P < .001$).

Figures 1 to 3 illustrate ROC curve analysis to detect the best cut-off points for the prediction of disease activity. In the multi-ROC analysis, prediction of disease activity by combined markers showed better performance than the single prediction by one biomarker. The diagnostic specificity, sensitivity, negative and positive predictive values, and accuracy of RA activity prediction increased to 100% when RDW at 13.7% and NLR at 3.4 were combined. SLE activity prediction by RDW at 14.0% with MPV at 10 fl showed 100% diagnostic specificity, 96.9% diagnostic sensitivity, 84.8% negative predictive value, 100% positive predictive value, and 97.3% diagnostic accuracy. In AS, combined activity prediction by RDW at 16.0% and MPV at 8.8 fl showed 100% diagnostic specificity, 98.5% diagnostic sensitivity, 96.8% negative predictive value, 100% positive predictive value, and 99.0% diagnostic accuracy.

Discussion

ESR and CRP levels and other indices are extensively employed as indicators of disease activity in systemic autoimmune rheumatological diseases; still, serum levels are affected by various other conditions, and normal levels do not consistently exclude active disease.44,45 Researchers are looking for other parameters that reflect disease activity because of the shortcomings of traditional acute-phase reactants (APRs).
| VARIABLE | CONTROL (N=100) | RA (N=100) | SLE (N=50) | AS (N=50) |
|----------|----------------|------------|------------|-----------|
| Age (years) | 73 (71–86) | 67 (59–71) | 64 (57–69) | 73 (64–87) |
| Sex, n (%) | Females: 51 (51.0%) | 81 (81.0%) | 84 (84.0%) | 63 (63.0%) |
| TLC (×10^3/µl) | 7.95 (5.92–11) | 7.4 (4.92–10.57) | 5.3 (3.3–8.5) | 8.65 (6–13.07) |
| Neut (×10^3/µl) | 5.05 (3.32–6.95) | 3.85 (2.6–6.8) | 3.2 (1.9–6.67) | 5.1 (3–7.72) |
| Lymph (×10^3/µl) | 2.55 (1.82–3.1) | 1.9 (1.2–2.6) | 1.25 (0.9–2.25) | 2.25 (1.5–3.925) |
| MON (×10^3/µl) | 0.6 (0.4–0.9) | 0.8 (0.5–1.2) | 0.6 (0.3–0.9) | 0.2–3.08 |
| HB (gm/dl) | 12.35 (10.02–13.6) | 9.55 (8.02–11.27) | 9.55 (8.02–11.27) | 11.05 (9.07–12.5) |
| Plt (×10^3/µl) | 243 (181.5–294.75) | 296 (212.25–376.75) | 237 (189–302.75) | 341.5 (283.5–453.5) |
| RDW (%) | 13.6 (12.4–14.55) | 11.55 (9.82–12.7) | 11.55 (9.82–12.7) | 11.55 (9.82–12.7) |
| MPV (fL) | 8.4 (7.7–9) | 9.5 (8.8–11) | 9.5 (8.8–11) | 9.5 (8.8–11) |
| NLR | 2.04 (1.63–2.58) | 2.31 (1.51–3.38) | 2.31 (1.51–3.38) | 2.31 (1.51–3.38) |
| PLR | 1.44 | 1.44 | 1.44 | 1.44 |
| SII | 204 (181.1–294.75) | 296 (212.25–376.75) | 237 (189–302.75) | 341.5 (283.5–453.5) |
| LMR | 4.06 (2.52–6) | 2.34 (1.42–3.65) | 2.34 (1.42–3.65) | 2.34 (1.42–3.65) |

Non-parametric quantitative results are expressed in medians (interquartile range [IQR]) and ranges while qualitative results are expressed in numbers (n) and percentages (%). Bold P-values indicate statistical significance.

P-values:
P > .05: non-significant; P < .05: significant; P < .01: highly significant.

HB, hemoglobin; LMR, lymphocyte-to-monocyte ratio; Lymph, lymphocytes; MON, monocytes; MPV, mean platelet volume; Neut., neutrophils; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; Plt, platelets; RDW, red cell distribution width; SII, systemic immune-inflammation index; TLC, total leukocytic count.
Inflammatory changes in rheumatological autoimmune disease involve changes in the number, shapes, and sizes of peripheral blood cells; accordingly, CBC-derived parameters like NLR, LMR, SII, and PLR have been recently shown to be markers of occult inflammation and activity in these diseases.46,47 These markers are simple, available, cheap, and can be done in any laboratory, yet clinicians rarely use them when studying hemograms, perhaps because they are unfamiliar with these important parameters.

Previous research looked into the relationship between various CBC-derived parameters and autoimmune diseases on an individual basis. To the best of our knowledge, this is the first study to examine the relationship between multiple hemogram-derived biomarkers, such as MPV, RDW, NLR, SII, LMR, and PLR, and the activity of various autoimmune rheumatological diseases. Furthermore, the relationship between hematomal indices and rheumatological diseases is still debatable. As a result, in our research, we attempted to collect all these biomarkers in a single study and examine their relationship to disease activity in three major autoimmune inflammatory diseases: RA, SLE, and AS.

The proportion of women in the study groups of SLE and RA patients was higher than men because both diseases are more common in women.48,49 However, because AS is more common in men, the percentage of males in our study’s AS patients was substantially larger than the number of females.50

| VARIABLE            | RA (N = 100) | SLE (n = 100) | AS (n = 50) |
|---------------------|-------------|---------------|-------------|
| ESR (55.5 (34–94.25)| 59 (38–89.5) | 57.5 (34.75–89.25) | 14.5 (8–36.5) |
| CRP (24 (12–48))   | 16.5 (12–30) | 14.5 (8–36.5) | 1.9 (1.17–2.82) |
| RF (56 (23–153.25))| 45 (29–78) | 35 (30–75) | 1 (1–3) |
| Anti-CCP (44 (12–99.75)) | 9 (6–13) | 1.9 (1.17–2.82) | 23 (46.0%) |
| DAS-28 (4.4 (2.8–5.9)) | 92 (96.0%) | 96 (96.0%) | 1.9 (1.17–2.82) |
| Positive RF        | 92 (96.0%) | 92 (96.0%) | 1.9 (1.17–2.82) |
| Positive anti-CCP  | 4.4 (2.8–5.9) | 9 (6–13) | 1 (1–3) |
| LF (4.4 (2.8–5.9)) | 92 (96.0%) | 92 (96.0%) | 23 (46.0%) |
| RF (56 (23–153.25))| 45 (29–78) | 35 (30–75) | 1 (1–3) |
| Anti-CCP (44 (12–99.75)) | 9 (6–13) | 1.9 (1.17–2.82) | 23 (46.0%) |
| Positive LF        | 92 (96.0%) | 92 (96.0%) | 1.9 (1.17–2.82) |
| LF (4.4 (2.8–5.9)) | 92 (96.0%) | 92 (96.0%) | 23 (46.0%) |

Anti-CCP, anti-cyclic citrullinated peptide; anti-dsDNA, anti-double-stranded DNA antibodies; ASDAS, ankylosing spondylitis disease activity score; CRP, C-reactive protein; DAS-28, disease activity score for RA; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; SLEDAI, systemic lupus erythematosus disease activity index.

Non-parametric quantitative results are expressed in medians (IQR) and ranges (Min. and Max.) while qualitative results are expressed in numbers (n) and percentages (%).

Very few studies investigated the ability of CBC parameters to differentiate between active RA and RA in remission,53,55,56 and most of the studies focused on the diagnostic value of CBC parameters in differentiating healthy controls from RA patients.

Accordingly, we investigated the discriminative ability of CBC-derived parameters for RA disease activity using an ROC analysis. In our study, RDW and MPV had a fair RA activity predictive performance. At the same time, NLR and SII showed poor performance. Remalante et al53 found that RDW and NLR had poor performance (AUC: 0.516, 0.629, respectively) with low sensitivity and specificity for predicting RA activity. Furthermore, patients with high activity RA had significantly higher RDW and MPV levels than those with low activity in our study, implying higher levels of inflammation in the former group and supporting our findings that RDW and MPV can help with clinical follow-up and activity prediction in RA patients.
## Table 3. Comparison of median (IQR) values of different activity groups in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and ankylosing spondylitis (AS).

|     | RA INACTIVE (N = 13) | LOW (N = 16) | MODERATE (N = 38) | HIGH (N = 33) | P-VALUE |
|-----|----------------------|--------------|-------------------|--------------|---------|
| RDW | 13.7 (12.85–14.7)    | 13.6 (12.97–13.87) | 16 (15–17)       | 17 (16.6–20) | <.001   |
| MPV | 8.8 (8.55–9.25)      | 8.75 (8.4–9.3)  | 9.5 (8.97–10.77) | 10.5 (9.9–11.55) | <.001   |
| NLR | 3.37 (2.13–5.97)     | 1.82 (1.34–3.37) | 2.19 (1.24–2.83) | 2.81 (1.53–3.46) | .064    |
| PLR | 162 (124.75–188.53)  | 159.77 (118.71–206.83) | 136.66 (99.73–229.84) | 174.61 (110.94–349.09) | .547    |
| SII | 721.83 (552.31–1533.38) | 587.78 (412.95–1027.39) | 701.51 (421.33–1133.04) | 617.62 (391.88–1098.93) | .46     |
| LMR | 2 (1.03–5.25)        | 2.28 (1.55–3.18) | 2.77 (1.62–3.91) | 2 (1.38–3.56) | .487    |

|     | SLE INACTIVE (N = 18) | LOW (N = 52) | MODERATE (N = 1) | HIGH (N = 29) | P-VALUE |
|-----|-----------------------|--------------|------------------|--------------|---------|
| RDW | 14 (13–15.42)         | 15.9 (14–17) | 17 (17–17)       | 19 (17.4–20) | <.001   |
| MPV | 8.8 (8.07–8.9)        | 9.35 (8.8–10) | 11 (11–11)       | 11 (9.55–11) | <.001   |
| NLR | 2 (1.57–3.48)         | 3.21 (1.65–3.59) | 2.8 (2.8–2.8) | 2.4 (1.35–3.81) | .68     |
| PLR | 114.0 (63.98–202.08)  | 117.85 (65.73–210.83) | 378 (378–378) | 265.33 (146.87–388.88) | <.001   |
| SII | 448.0 (241.73–996.29) | 458.86 (250.77–849.97) | 529.2 (529.2–529.2) | 466.66 (168.06–1281.63) | .965    |
| LMR | 2.15 (1.70–5.27)      | 2.41 (1.72–4.62) | 0.55 (0.55–0.55) | 1.66 (0.95–2.83) | .016    |

|     | AS INACTIVE (N = 15) | LOW (N = 16) | HIGH (N = 19) | P-VALUE |
|-----|----------------------|--------------|---------------|---------|
| RDW | 15 (14–15.2)         | 17.5 (16.12–18) | 20 (19–22) | <.001   |
| MPV | 8.9 (8.8–9.7)        | 12.5 (10.25–14) | 13 (10–16) | <.001   |
| NLR | 1.93 (1.55–2.33)     | 2.33 (1.75–3.37) | 2.33 (1.93–3.07) | .128    |
| PLR | 145.9 (139.11–188.8) | 181.0 (110.06–271.68) | 160.35 (95.81–322.85) | .866    |
| SII | 697.66 (546.07–887.36) | 792.73 (426.94–1141.5) | 904 (719.76–1585.39) | .068    |
| LMR | 2.44 (1.63–3.8)      | 2.125 (1.22–2.81) | 2 (1.11–3) | .408    |

|     | P-VALUE   |
|-----|-----------|
| RDW | <.001     |
| MPV | <.001     |

LMR, lymphocyte-to-monocyte ratio; MPV, mean platelet volume; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; RDW, red cell distribution width; SII, systemic immune-inflammation index.

P-value > 0.05: non significant; P-value < 0.05: significant; Bold P-values indicate statistical significance.
Regarding SLE patients included in our study, RDW, MPV, PLR, and NLR were significantly higher, and LMR was significantly lower than healthy controls. There was no statistically significant difference in SII between our SLE patients and controls. MPV and RDW distinguished inactive SLE patients from those with low disease activity and low disease activity from high disease activity. In addition, the AUC was higher for RDW and MPV than other indices. In contrast to our results, Peirovy et al. concluded that NLR, MPV, and RDW could not differentiate between SLE cases with high disease activity from those with low disease activity.

Our results regarding MPV were consistent with those of Yavuz and Ece, who studied juvenile SLE patients and found that MPV was significantly higher in SLE patients than controls and increased with disease activity. In contrast, in a study on 50 SLE patients, Khan et al. reported that MPV decreased with SLE activity and showed an inverse relationship with ESR and SLEDAI. Also, in a study by Safak et al., active SLE patients had lower MPV levels than patients in remission and healthy controls. These discrepancies could be explained by variances in patients’ disease activity levels, and ongoing therapies as MPV levels are affected by disease activity and therapy.

In our SLE patients, only RDW, MPV, and PLR were positively correlated with ESR, CRP, anti-dsDNA titer, and SLEDAI score, with no correlation between NLR and activity markers, which is partially against the results of Peirovy et al., who found positive correlations between SLEDAI and NLR and PLR. Although the activity indices used in our study (SLEDAI) differ from those used in their study (SLEDAI-2k), our results appear to be more reliable because the aforementioned hematological indices are correlated with multiple activity markers and indicators, namely, CRP, ESR, and anti-dsDNA titer, not just the SLEDAI score.

Only the SLE group from the other rheumatic inflammatory disorders studied in our study had a significantly higher

| Table 4. Correlations of different CBC parameters with disease activity markers and scores in RA, SLE, and AS patients. |
| RA | RDW | MPV | NLR | PLR | SII | LMR |
| ESR | 0.547 <.001 | 0.398 <.001 | 0.179 0.074 | 0.09 0.372 | 0.126 0.213 | −0.041 .685 |
| CRP | 0.417 <.001 | 0.348 <.001 | 0.005 0.957 | 0.078 0.442 | 0.116 0.249 | −0.064 .528 |
| RF | 0.617 <.001 | 0.532 <.001 | 0.089 0.381 | −0.027 0.789 | 0.024 0.812 | 0.045 .657 |
| Anti-CCP | 0.552 <.001 | 0.481 <.001 | −0.03 0.768 | 0.081 0.421 | 0.028 0.784 | −0.035 .729 |
| DAS.28 | 0.647 <.001 | 0.51 <.001 | −0.046 0.653 | 0.089 0.379 | −0.053 0.602 | −0.064 .530 |
| SLE | RDW | MPV | NLR | PLR | SII | LMR |
| ESR | 0.505 <.001 | 0.380 <.001 | 0.057 0.574 | 0.266 .008 | 0.124 0.217 | −0.062 .540 |
| CRP | 0.375 <.001 | 0.394 <.001 | −0.067 0.509 | 0.264 .008 | 0.022 0.831 | −0.249 .013 |
| DNA | 0.603 <.001 | 0.341 <.001 | −0.078 0.439 | 0.305 .002 | −0.057 0.572 | −0.178 .076 |
| SLEDAI | 0.623 <.001 | 0.514 <.001 | 0.12 0.236 | 0.425 <.001 | 0.072 0.479 | −0.221 .027 |
| AS | RDW | MPV | NLR | PLR | SII | LMR |
| ESR | 0.794 <.001 | 0.697 <.001 | 0.398 .004 | 0.072 0.618 | 0.411 .003 | −0.284 .045 |
| CRP | 0.722 <.001 | 0.61 <.001 | 0.363 .009 | 0.050 0.732 | 0.446 .001 | −0.292 .039 |
| ASAS | 0.834 <.001 | 0.612 <.001 | 0.291 .040 | 0.038 0.793 | 0.349 .013 | −0.176 .221 |

LMR, lymphocyte-to-monocyte ratio; MPV, mean platelet volume; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; RDW, red cell distribution width; SII, systemic immune-inflammation index.
P-value >.05: non significant; P-value <.05: significant; Bold P-values indicate statistical significance.
Figure 1. ROC curve analysis showing the diagnostic performance of the studied parameters for discriminating active RA patients from those inactive.

Figure 2. ROC curve analysis showing the diagnostic performance of the studied parameters for discriminating active SLE patients from those in remission.
NLR than controls, implying that the NLR could be a useful biomarker for SLE diagnosis. On the other side, NLR was not correlated with disease activity indicated by ESR, CRP, anti-dsDNA, and the SLEDAI score; also, we found no significant difference in the NLR of low active and inactive SLE patients (\(P= .288\)) or between low vs moderate activity groups (\(P= .695\)) indicating that it might be a good diagnostic marker, but not an activity marker for SLE. Consistent with our results, the findings of Oehadian et al, who found no significant difference in NLR between SLE patients with mild and moderate activity, 2.59 (1.01–10.92) vs 2.01 (1.38–3.98), \(P= .412\). In contrast, Papachristodoulou et al, concluded that high NLR was associated with SLE activity.

In the present study, all hemogram-derived indices showed significant differences \((P<.001)\) between the AS cases and healthy controls, with RDW, MPV, PLR, and SII increasing and LMR decreasing. In comparison, there was not any statistical difference regarding NLR compared with healthy controls \((P= .134)\). Regarding RDW, our findings align with a recent meta-analysis study by Song and Lee. They included 11 studies and concluded that RDW significantly increased in AS patients compared with controls. Still, they failed to find any difference regarding MPV and PLR, recommending further studies to clarify their findings. Also, another study on AS patients by Peng et al showed increased RDW with significant difference compared with healthy individuals (13.66 ± 0.77% vs 12.77 ± 0.47%, \(P<.01\)). On the other hand, our findings were against another study that did not find any significant difference regarding RDW, PLR, and MPV \((P> .05)\).

As for NLR did not show any significant difference between AS patients and healthy controls \((P= .134)\), but there was a significant difference between inactive and high disease activity patient groups \((P= .046)\). Also, it was correlated with ESR, CRP, and ASDAS scores. Partially consistent with our results is a very recent study by Eroğlu et al, who concluded that NLR levels were similar between AS patients and healthy controls; NLR levels were only weakly correlated with CRP levels. Similarly, Mercan et al found no statistical difference between AS patients and controls regarding NLR, but found a correlation between NLR with ESR and CRP; our results seem to add more information regarding the use of NLR in AS, it might not be a diagnostic marker but is well correlated with disease activity markers and indices.

Our results can be explained by the following: AS is characterized by chronic inflammation caused by interleukin (IL)-6 and tumor necrosis factor released altering RBC maturation and life span, contributing to an increase in RDW. Platelets, with their increased counts, can release a variety of mediators, including thromboxanes, which cause inflammation. MPV correlates with platelet function and activation.

Figure 3. ROC curve analysis showing the diagnostic performance of the studied parameters for discriminating active AS patients from those in remission.
SII, a new inflammatory marker, can provide a more comprehensive picture of the body’s inflammation and immune balance. SII level in patients with AS was significantly higher than that in controls (P < .001). The SII level was significantly higher in the AS patient group with high activity than the inactive patient (P = .013). In addition, it was correlated with ESR (P = .003), CRP (P = .001), and ASDAS (P = .013). A study by Wu et al12 is consistent with our findings, except that they used bath ankylosing spondylitis disease activity index (BASDAI) instead of ASDAS as an activity index. Our results support Wu et al12 results that SII could be a novel biomarker for assessing AS activity.

In terms of AS, the ROC analysis showed that RDW and MPV had the best predictive performance for disease activity. Sezgin et al12 studied RDW and MPV in AS patients concluding at a cut-off value of 14.8% and 10.4 fl, respectively, the AUC was 0.76 and 0.58, respectively. Our study showed that integrated markers in the multi-ROC analysis performed better than a single biomarker. Combining RDW (13.7%) and NLR (3.4%) improved the predictive performance for RA activity. RDW at 14% with MPV at 10 fl improved the predictive performance for SLE activity. In AS, combining RDW at 16.0% and MPV at 8.8 fl improved AS activity prediction. One limitation of our study is its single-center nature; larger multicenter studies on wider scales are recommended to confirm our findings.

Clinical follow-up and disease activity prediction in patients with rheumatological diseases could be made by simple, readily available, and inexpensive indicators derived from simple CBC analysis (RDW, MPV, NLR, PLR, LMR, and SII). To which clinicians must pay attention for better prediction of disease’s course and prognosis of disease.

In conclusion, of all the included CBC-derived indicators in our study, RDW and MPV had the best predictive performance for disease activity in the three studied rheumatological diseases a finding that can help with clinical follow-up.

Author Contributions
All authors made major contributions to this work, whether it was in the conception, study design, data acquisition, analysis, and interpretation, or in the drafting, revising, or reviewing of the article, and they all gave final approval to the version that would be published.

Availability of Data and Materials
On request, all data will be provided.

Ethical Approval and Consent to Participate
On the basis of ethical concerns, the current study protocol was authorized by the Research Ethics Committee of Ain Shams University Faculty of Medicine (FWA 00017585). Before any of the individuals could participate in the study, all procedures were described to them and their informed consent was obtained. The Declaration of Helsinki was followed in this research.

ORCID iDs
Sara Ibrahim Taha  https://orcid.org/0000-0001-8224-8701
Nouran Magdy Moustafa  https://orcid.org/0000-0003-3494-9372

REFERENCES
1. Zochling J, Braun J. Mortality in rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol. 2009;27:812-813.
2. Anolik JH. B cell biology and dysfunction in SLE. Bull NYU Hosp Jt Dis. 2007;65:182-186.
3. Nossef JC. SLE/ACR damage index In Afro-Caribbean patients with systemic lupus erythematosus: changes in and relationship to disease activity, corticosteroid therapy, and prognosis. J Rheumatol. 1998;25:654-659.
4. Kugyelka R, Kohl Z, Oloae K, et al. Enigma of IL-17 and Th17 Cells in rheumatoid arthritis and in autoimmune animal models of arthritis. Mediators Inflamm. 2016;2016:6145810. doi:10.1155/2016/6145810.
5. Sh-dtran NJ. The transplantations of HLA-B27. J R Soc Med. 2004;97:10-14. doi:10.1258/jrsm.97.11.11.
6. Ren L, Li J, Luo R, Tang R, Zhu S, Wan L. Efficacy of antitumor necrosis factor (α) agents on patients with ankylosing spondylitis. Am J Med Sci. 2013;346:455-461. doi:10.1097/MAJ.0b013e318292eaa3.
7. Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res. 2002;4:307-321. doi:10.1186/ar592.
8. Colgazier CL, Sutej PG. Laboratory testing in the rheumatic diseases: a practical review. South Med J. 2005;98:185-191. doi:10.1097/01.SMJ.0000153752.22146.E9.
9. Merenc R, Bitrik B, Tufan A, et al. The association between neutrophil/lympho- cyte ratio and disease activity in rheumatoid arthritis and ankylosing spondylitis. J Clin Lab Anal. 2016;30:597-601. doi:10.1002/jcla.21908.
10. Chen Q, Chen DY, Xu ZX, Liu YY, Yin TT, Li D. Platelet/lymphocyte, lymphocyte/monocyte, and neutrophil/lymphocyte ratios as biomarkers in patients with rheumatoid arthritis and rheumatoid arthritis-associated interstitial lung disease. Med Sci Monit. 2019;25:6474-6481. doi:10.12659/MSM.916583.
11. Gulsun O, Feyza UL, Aktas OS. Parameters of total blood count; might they be indicators of inflammation in rheumatoid arthritis and ankylosing spondylitis? Acta Medica Mediterranea. 2018;34:751-756. doi:10.19193/0393-6384_2018_6_268.
12. Sezgin M, Teker D, Kankan A, et al. Serum RDW and MPV in Ankylosing spondylitis: can they show the disease activity? Clin Hemorheol Microcirc. 2017;65:1-20. doi:10.3225/CH-7667.
13. Ural E, Şan İ, Belçoğlu B, Sahin A. Role of hematological parameters in COVID-19 patients in the emergency room. Biomark Med. 2020;14:1207-1215. doi:10.2217/bmm-2020.
14. Taha SI, Samaan SF, Baouny SA, et al. Role of hemogram-derived ratios and systemic-immune inflammation index in prediction of COVID-19 progression in Egyptian patients. Microbes Infect Dis. 2021;2:643-622. doi:10.21608/mid.2021.84684.1168.
15. Aktas G, Sit M, Tekce H, et al. Mean platelet volume in nasal polyps. West Indian Med J. 2013;62:513-518. doi:10.7727/wimj.2013.0311.
16. Aktras G, Akelik A, Tekce BK, Tekelioğlu V, Sit M, Savlı H. Red cell distribution width and mean platelet volume in patients with irritable bowel syndrome. Prog Gastroenterol. 2014;9:160-163. doi:10.5114/pg.2014.443578.
17. Aktras G, Kocak MZ, Duman TT, et al. Mean platelet volume (MPV) as an inflammatory marker in type 2 diabetes mellitus and obesity. Bali Med J. 2018;7:650-653.
18. Aktras G, Cakiroglu B, Sit M, et al. Mean platelet volume: a simple indicator of chronic prostatitis. Acta Medica Mediterranea. 2013;29:551-554.
19. Cakir L, Aktas G, Enginyurt O, Cakir SA. Mean platelet volume increases in type 2 diabetes mellitus independent of HbA1c level. Acta Medica Mediterranea. 2014;30:425-428.
20. Dagistan Y, Dagistan E, Gezici AR, et al. Could red cell distribution width and mean platelet volume be a predictor for lumbar disc hernia? Idgleygzy Sz. 2016;69:411-414. doi:10.18071/iss.69.0411.
21. Sincer I, Gunes Y, Manisiroglu AK, Cosgun M, Aktas G. Association of mean platelet volume and red blood cell distribution width with coronary collateral development in stable coronary artery disease. Postepy Kardiolog Interwencyjnej. 2018;14:263-269. doi:10.5114/pg.2018.78329.
22. Tekce H, Ken Tekce B, Aktas G, Tanısoy M, Sit M. The evaluation of red cell distribution width in chronic hemodialysis patients. Int J Nephrol. 2014;2014:754370. doi:10.1155/2014/754370.
23. Aktras G, Sit M, Dikbas O, et al. Could red cell distribution width be a marker in Hashimoto’s thyroiditis? Exp Clin Endocrinol Diabetes. 2014;122:572-574. doi:10.1055/s-0034-136263.
4. Weckerle CE, Niewold TB. The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clin Rev Allergy Immunol. 2011;40:42-49. doi:10.1007/s12016-009-0009-9.

5. van Vollenhoven RF. Sex differences in rheumatoid arthritis: more than meets the eye. BMC Med. 2009;7:12. doi:10.1186/1741-7015-7-12.

6. Moll JM, Haibl M, Mackie IF, Wright V. Association between ankylosing spondylitis, psoriatic arthritis, Reiter’s disease, the intestinal arthropathies, and Behcet’s syndrome. Medicine (Baltimore). 1974;53:343-346. doi:10.1097/00005792-197409000-00009.

7. Al-Rawi ZS, Goral AI, Al-Bayati AA. Red blood cell distribution width in rheumatoid arthritis. Mediators Rheum. 2018;29:38-42. doi:10.1186/s13079-018-1.3.18.

8. Lin F, Wang X, Liang B. Blood cell distribution width in rheumatoid arthritis, ankylosing spondylitis and osteoarthritis: true inflammatory index or effect of anemia? Ann Clin Lab Sci. 2018;48:301-307.

9. Remalante PFM, Salido EO, Pongserga EG, Gauvin DTT. Red cell distribution width and neutrophil/lymphocyte ratio in rheumatoid arthritis. Rheumatol Int. 2016;36:1137-1143. doi:10.1007/s00296-016-2602-0.

10. Yildirim A, Surucu G, Dogan S, Karabiber M. Relationship between disease activity and hearing impairment in patients with rheumatoid arthritis compared with controls. Clin Rheumatol. 2016;35:309-314. doi:10.1007/s10067-015-2617-y.

11. Tser C, Sciglio M, Kanik A, et al. Can mean platelet volume and red blood cell distribution width show disease activity in rheumatoid arthritis? Biomark Med. 2016;10:976-977. doi:10.2217/bmm-2016.

12. Horta-Bags AM, Romero-Figueroa MDS. Clinical utility of red blood cell distribution width in inflammatory and non-inflammatory joint diseases. Int J Rheum Dis. 2020;23:923-927. doi:10.1111/iijd.14029.

13. Peirozy A, Malek Mahdavi A, Khahabai A, Hajilooi M, Sakhina E, Rashizhadch N. Clinical Usefulness of Hematologic Indices as Predictive Parameters for Systemic Lupus Erythematosus. Med Sci Monit. 2020;26:519-528. doi:10.1902/1421-8158.1.99002.

14. Yavuz S, Ece A. Mean platelet volume as an indicator of disease activity in juvenile idiopathic arthritis. J Rheumatol. 2013;40:327-331. doi:10.3899/jr.12.376.

15. Khan A, Haidar I, Ayub M, Khan S. Mean Platelet Volume (MPV) as an indicator of disease activity and severity in lupus. F1000Res. 2017;6:126. doi:10.2888/jr.1068.

16. Sazaf S, Ulu AU, Serdal K, Turker T, Soner S, Lofth A. Association between mean platelet volume levels and inflammation in SLE patients presented with arthritis. Adv Health Sci Educ. 2018;23:917-922. doi:10.1007/s10459-017-9631-8.

17. Yolkas S, Yildirim A, Gozel N, Üz B, Koca SS. Hematological indices may be useful in the diagnosis of systemic lupus erythematosus and in determining disease activity in Behcet’s disease. Med Prim Care. 2016;25:510-516. doi:10.1179/1369219016z.000000004.

18. Ochadhan A, Surudina H, Dewi S, Pramudyo R, Alijabba H. The role of neutrophil lymphocyte count ratio as an inflammatory marker in systemic lupus erythematosus. Acta Med Indones. 2013;45:170-174.

19. Papachristodoulou E, Kakoullis L, Parelis S, Hajiroussos V, Christophi C, Parperis K. Investigating the neutrophil to lymphocyte ratio as a marker of SLE disease activity, healthrelated quality of life and depression [abstract: 0878]. Arthritis Rheumatol. 2021;73:878.

20. Song GG, Lee YH. Red cell distribution width, platelet-to-lymphocyte ratio, and mean platelet volume in ankylosing spondylitis and their correlations with inflammation: a meta-analysis. J Rheumatol. 2020;35:898-909. doi:10.3899/jr.12.975.

21. Morrell CN, Aggrey AA, Guo L, Modjeski KL. Emerging roles for platelet-dependent S1P1 signaling in the eye. Adv Ophthalmol. 2020;59:1-10. doi:10.1097/IOOP.0000000000002391.

22. Boban N, Alpaycu M, Aadan M, et al. Mean platelet volume, red cell distribution width, platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios in patients with ankylosing spondylitis and their relationships with high-frequency hearing thresholds. Eur Arch Otorhinolaryngol. 2016;273:3653-3657. doi:10.1007/s00405-016-3722-9.

23. Eroglu DS, Turgutalp M, Serer S, et al. Complete blood count derived haematological parameters do not correlate with disease activity in patients with radiographic axial spondyloarthritis. Ulus Romatol Derg. 2021;13:6-11.

24. Straat M, van Bruggen R, de Korte D, Juffermans NP. Red blood cell clearance in transfusion. Transfus Med Hemother. 2012;39:353-361. doi:10.1159/000342249.

25. Shi L, Qin X, Wang H, et al. Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma. Oncotarget. 2017;8:18792-18801. doi:10.18632/oncotarget.13326.

26. Morris CN, Aggrey AA, Guo L, Modjeski KL. Emerging roles for platelets as immune and inflammatory cells. Blood. 2014;123:2759-2767. doi:10.1182/blood-2013-10-521715.

27. Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20:6122-6122. doi:10.1158/1977-7827.CCR-13-1322.

28. Wu J, Yan L, Chai K. Systemic immune-inflammation index is associated with disease activity in patients with ankylosing spondylitis. J Clin Lab Anal. 2021;35:e23964. doi:10.1002/jcla.23964.